Complement factor H: a novel innate immune checkpoint in cancer immunotherapy
R Saxena, EB Gottlin, MJ Campa… - Frontiers in Cell and …, 2024 - frontiersin.org
The elimination of cancer cells critically depends on the immune system. However, cancers
have evolved a variety of defense mechanisms to evade immune monitoring, leading to …
have evolved a variety of defense mechanisms to evade immune monitoring, leading to …
Hypoxic ischemic brain injury: animal models reveal new mechanisms of melatonin-mediated neuroprotection
S Perrone, S Carloni, VG Dell'Orto, L Filonzi… - Reviews in the …, 2024 - degruyter.com
Oxidative stress (OS) and inflammation play a key role in the development of hypoxic–
ischemic (H–I) induced brain damage. Following H–I, rapid neuronal death occurs during …
ischemic (H–I) induced brain damage. Following H–I, rapid neuronal death occurs during …
Complement regulators as novel targets for anti-cancer therapy: A comprehensive review
R Saxena, EB Gottlin, MJ Campa, YW He… - Seminars in …, 2025 - Elsevier
Cancer remains a formidable global health challenge requiring the continued exploration of
innovative therapeutic approaches. While traditional treatment strategies including surgery …
innovative therapeutic approaches. While traditional treatment strategies including surgery …
Effect of Severe Renal Impairment on Pharmacokinetics, Safety, and Tolerability of ACT‐1014‐6470, a Novel Oral Complement Factor 5a Receptor 1 Antagonist
A Hammann‐Hänni, P Kaufmann… - Clinical …, 2023 - Wiley Online Library
The aim of this study was to examine the safety and the effect of severe renal impairment
(RI) on the pharmacokinetics of ACT‐1014‐6470, a novel oral complement factor 5a …
(RI) on the pharmacokinetics of ACT‐1014‐6470, a novel oral complement factor 5a …